MedTrace Logo

A Multi-center Study of Apixaban(APPROACH)

NCT04550637 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-10-18

No results posted yet for this study

Summary

The aim of the study is to enroll approximately 200 cases from 10 research centers nationwide, completed left atrial appendage occlusion (LAAO) successfully, and give apixaban (5 mg bid) postoperatively.

Conditions

  • Evaluate the Safety and Efficacy of Apixaban

Interventions

DRUG

Oral apixaban

apixaban (5 mg bid) is given until 12 weeks after surgery

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Junbo Ge · Fudan University

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-04
Primary Completion
2023-12-31
Completion
2024-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04550637 on ClinicalTrials.gov